SPX4,092.24+12.13 0.30%
DIA345.51-0.64 -0.18%
IXIC11,524.47+56.48 0.49%

Truist Securities Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $29

Benzinga · 11/16/2022 07:11
Truist Securities analyst Robyn Karnauskas initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $29.